MedTrace Logo

Safety Study of Orally Administered Curcuminoids in Adult Subjects With Cystic Fibrosis

NCT00219882 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2007-12-25

No results posted yet for this study

Summary

The purpose of this study is to assess the safety of advancing doses of curcuminoids administered orally for fourteen consecutive days in adult subjects with cystic fibrosis (CF) who are homozygous for ΔF508 CFTR.

Conditions

Interventions

DRUG

standardized turmeric root extract

1.5 gm of standardized tumeric root extract three times per day for seven consecutive days, followed by 3 gm of standardized tumeric root extract three times per day for seven consecutive days

Sponsors & Collaborators

  • Seer Pharmaceuticals

    collaborator INDUSTRY

  • CF Therapeutics Development Network Coordinating Center

    collaborator NETWORK

  • Cystic Fibrosis Foundation

    collaborator OTHER

  • Ramsey, Bonnie, MD

    lead INDIV

Principal Investigators

  • Chris Goss, MD, MSc · University of Washington

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Completion
2006-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00219882 on ClinicalTrials.gov